Clinical data of Medigene's Dendritic Cell vaccines to be presented at ASH conference
The Oslo University Hospital has an agreement with Medigene for use of Medigene's new generation DC vaccines for their ongoing academic clinical studies.
To view the abstract of the presentation please visit: https://ash.confex.com/ash/2014/webprogram/Paper74148.html
Furthermore, Medigene informs that an abstract on an investigator initiated phase II clinical trial with Medigene's DC vaccines for the treatment of prostate cancer currently being conducted by the Oslo University Hospital can be found at: http://www.eacr.org/pivac14/downloads/PIVAC14%20online%20prog%20book.pdf
(p. 17 of the abstract book).
About Medigene's DC vaccines: The platform for the development of antigen-tailored DC vaccines is the most advanced platform of the three highly innovative and complementary immunotherapy platforms of Medigene Immunotherapies (formerly Trianta Immunotherapies), which was recently acquired by Medigene AG. Currently the DC vaccines are being evaluated in two ongoing investigator-initiated trials in clinical phases II (prostate cancer) and I/II (AML, acute myeloid leukaemia). Medigene concentrates on the further development of DC vaccines in hematological malignancies and plans to initiate a further clinical study in AML in 2014.
Medigene's dendritic cell product platform allows the design of new generation dendritic cell vaccines. Dendritic cells can take up antigens efficiently, process them and present them on their surface in a form that can activate antigen-specifc T cells to divide and mature and thus enable the T cells to attack tumour cells. Dendritic cells can also induce natural killer cells to become active and attack tumour cells. Medigene Immunotherapies has established new, fast and efficient methods for preparation of autologous (patient-specific) mature dendritic cells that have relevant characteristics to activate both T cells and natural killer cells. They are developed to carry multiple tumour antigens and can be tailored to treat various types of cancer, suited for treatment of minimal residual disease or use in combination therapies.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. Medigene ImmunotherapiesTM is a registered trademark of Medigene Immunotherapies GmbH. Trianta ImmunotherapiesTM is a registered trademark of Medigene Immunotherapies GmbH. These trademarks may be owned or licensed in select locations only.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.
Press releases you might also be interested in
Weitere Informationen zum Thema "Forschung und Entwicklung":
Neues Jobprofil, neue Ausbildung – KI-Manager
68 Prozent der Deutschen möchten KI selbst erleben – so eine Studie im Auftrag des Digitalverbandes Bitkom. Viele erleben KI bereits, ohne es vielleicht zu wissen: Sprachassistenten wie Alexa oder Siri setzten auf diese Technologie. Und demnächst kann man sich sogar zum KI-Manager ausbilden lassen.Weiterlesen